A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Anticancer Research

• Publication date

  2001-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 11712813
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inheritance of the 194Trp and the 399Gln variant alleles of the DNA repair gene XRCC1 are associated with increased risk of early-onset colorectal carcinoma in Egypt.

  2000cited by this paper
• Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells.

  2000cited by this paper
• XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency.

  1999cited by this paper
• Requirement for the Xrcc1 DNA base excision repair gene during early mouse development.

  1999cited by this paper
• Base excision repair of oxidative DNA damage activated by XPG protein.

  1999cited by this paper
• Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts.

  1999cited by this paper
• ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy.

  1998cited by this paper
• Oxaliplatin: mechanism of action and antineoplastic activity.

  1998cited by this paper
• Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer.

  1998cited by this paper
• Structure of an XRCC1 BRCT domain: a new protein–protein interaction module

  1998cited by this paper
• XRCC1 Is Specifically Associated with Poly(ADP-Ribose) Polymerase and Negatively Regulates Its Activity following DNA Damage

  1998cited by this paper
• Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells.

  1997cited by this paper
• Cisplatin and Adriamycin Resistance Are Associated with MutLα and Mismatch Repair Deficiency in an Ovarian Tumor Cell Line*

  1996cited by this paper
• A Chinese hamster ovary cell mutant (EM-C11) with sensitivity to simple alkylating agents and a very high level of sister chromatid exchanges.

  1992cited by this paper
• Molecular cloning of the human XRCC1 gene, which corrects defective DNA strand break repair and sister chromatid exchange

  1990cited by this paper
• Assignment of a human DNA-repair gene associated with sister-chromatid exchange to chromosome 19.

  1986cited by this paper
• Kinetic analysis of the in vitro binding of radioactive cis- and trans-dichlorodiammineplatinum(II) to DNA.

  1980cited by this paper

• WBP1 regulates mitochondrial function and ferroptosis to modulate chemoresistance in colorectal cancer

  2025cites this paper
• Pharmacogenomics and Personalized Medicine

  2024cites this paper
• Integrative Bioinformatics Analysis: Unraveling Variant Signatures and Single-Nucleotide Polymorphism Markers Associated with 5-FU-Based Chemotherapy Resistance in Colorectal Cancer Patients

  2024cites this paper
• The role of DNA damage response in chemo- and radio-resistance of cancer cells: Can DDR inhibitors sole the problem?

  2021cites this paper
• Genomic and epigenomic biomarkers in colorectal cancer: From diagnosis to therapy.

  2021cites this paper
• Pharmacogenomic Assessment of Patients with Colorectal Cancer and Potential Treatments

  2020cites this paper
• Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survival

  2020cites this paper
• Adjuvant and Neoadjuvant Therapy for Colorectal Cancer

  2019cites this paper
• A case report of small bowel adenocarcinoma with liver metastases: genetic profiling and clinical management

  2019cites this paper
• Predictive Biomarkers in Metastatic Colorectal Cancer: A Systematic Review.

  2019cites this paper
• Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy.

  2018cites this paper
• Genetic variants as potential predictive biomarkers in advanced colorectal cancer patients treated with oxaliplatin‐based chemotherapy

  2018influential citation
• Chapter 4 Acquired and Intrinsic Resistance to Colorectal Cancer Treatment

  2018cites this paper
• Acquired and intrinsic resistance to colorectal cancer treatment

  2017cites this paper
• Correlations between microsatellite instability, ERCC1/XRCC1 polymorphism and clinical characteristics, and FOLFOX adjuvant chemotherapy effect of colorectal cancer patients.

  2017cites this paper
• Prognostic and Predictive Significance of Base Excision Repair in Human Cancers

  2017cites this paper
• Pharmacogenetic and ethnicity influence on oxaliplatin therapy for colorectal cancer: a meta-analysis.

  2016cites this paper
• Single Nucleotide Polymorphisms as Prognostic and Predictive Factors of Adjuvant Chemotherapy in Colorectal Cancer of Stages I and II

  2016cites this paper
• Role of pharmacogenetics for the improvement of cancer treatment

  2016cites this paper
• Impact of XRCC1, GSTP1, and GSTM1 Polymorphisms on the Survival of Ovarian Carcinoma Patients Treated with Chemotherapy

  2016cites this paper
• Rational selection of predictive pharmacogenomics test for the Fluoropyrimidine/Oxaliplatin based therapy.

  2015cites this paper
• Exploiting Base Excision Repair to Improve Therapeutic Approaches for Pancreatic Cancer

  2015cites this paper
• Genetic variants in DNA repair genes as potential predictive markers for oxaliplatin chemotherapy in colorectal cancer

  2015cites this paper
• XRCC1 and ERCC1 polymorphisms are related to susceptibility and survival of colorectal cancer in the Chinese population.

  2015cites this paper
• Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

  2014cites this paper
• The Complexity of Colorectal Cancer Biology — Putting Bricks on the Path to Personalized Medicine

  2014cites this paper
• ERCC1, XRCC1 and GSTP1 Single Nucleotide Polymorphisms and Survival of Patients with Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy

  2014influential citation
• Predictive response biomarkers in rectal cancer neoadjuvant treatment.

  2014cites this paper
• X‐ray repair cross‐complementing 1 polymorphism and prognosis of platinum‐based chemotherapy in gastric and colorectal cancer: A meta‐analysis

  2014influential citation
• Towards functional multiscale analysis of colorectal cancer

  2014cites this paper
• Aus dem Institut für Klinische Pharmakologie (Prof. Dr. med. J. Brockmöller) im Zentrum Pharmakologie und Toxikologie der Medizinischen Fakultät der Universität Göttingen Identifizierung genetischer Biomarker für die Wirksamkeit von Oxaliplatin: Kandidatengen-bezogene und Genom-weite Analysen

  2014cites this paper
• Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity.

  2013cites this paper
• Predicting chemotherapeutic response and toxicity in colorectal cancer

  2013cites this paper
• DNA Base Excision Repair: Evolving Biomarkers for Personalized Therapies in Cancer

  2013cites this paper
• Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer

  2013cites this paper
• Predictive markers for neoadjuvant chemotherapy in advanced squamous cell carcinoma of maxillary sinus: Preliminary report

  2013cites this paper
• Association between XRCC1 and XRCC3 Polymorphisms with Lung Cancer Risk: A Meta-Analysis from Case-Control Studies

  2013cites this paper
• XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis

  2013influential citation
• Individualized therapy for metastatic colorectal cancer

  2013cites this paper
• Molecular mechanic and monte carlo study of polymorphism effects on biophysical chemistry properties of XRCC1 BRCT2 domain

  2013cites this paper
• Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer

  2013cites this paper
• RETRACTED: Genetic Polymorphism of XRCC1 Correlated with Response to Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer

  2013cites this paper
• CK2 as a Logical Target in Cancer Therapy: Potential for Combining CK2 Inhibitors with Various Classes of Cancer Therapeutic Agents

  2013cites this paper
• Investigating the genetics and pharmacogenetics of bowel cancer

  2013cites this paper
• Personalized Cancer Medicine

  2012cites this paper
• Current trends in the chemotherapy of colorectal cancer.

  2012cites this paper
• Genetic Polymorphism of XRCC1 Correlated with Response to Oxaliplatin-Based Chemotherapy in Advanced Colorectal Cancer

  2012cites this paper
• Estudio farmacogenético del cáncer colorrectal

  2012cites this paper
• Farmacogenética en el tratamiento del cáncer colorrectal

  2012cites this paper
• Cancer Pharmacogenomics

  2012cites this paper
• Detection of XRCC1 gene polymorphisms in Egyptian patients with acute myeloid leukemia

  2012influential citation
• Pharmacogenetics and Pharmacogenomics of Colorectal Cancer: Moving Towards Personalized Medicine

  2012cites this paper
• Pharmacogenomics and metastatic colorectal cancer: Current knowledge and perspectives

  2012cites this paper
• The development and application of SNP discovery technologies from 2005 to 2012

  2012cites this paper
• The potential of the PARP-1 inhibitor, AGO14699, in human cancers defective in homologous recombination DNA repair

  2012cites this paper
• Tratamiento neoadyuvante en cáncer de recto: comparación de esquemas de radioquimioterapia

  2012cites this paper
• 5 Current insights in the role of heritable genetic variation in the pharmacokinetics and pharmacodynamics of anti-cancer drugs

  2011cites this paper
• PREOPERATIVE CHEMORADIOTHERAPY : POLYMORPHISMS IN THYMIDYLATE SYNTHASE , EPIDERMAL GROWTH FACTOR RECEPTOR , GSTP 1 , AND DNA REPAIR GENES

  2011cites this paper
• Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer.

  2011cites this paper
• Role of genetic polymorphisms and mutations in colorectal cancer therapy (Review).

  2011cites this paper
• Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes.

  2011cites this paper
• Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group

  2011cites this paper
• Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer.

  2011cites this paper
• Biomarker-based selection of therapy for colorectal cancer.

  2011cites this paper
• Role of Tumor Tissue Analysis in Rectal Cancer Pharmacogenetics

  2011cites this paper
• Pharmacokinetic and metabolism determinants of fluoropyrimidines and oxaliplatin activity in treatment of colorectal patients.

  2011cites this paper
• Revisiting the frontiers of pharmacogenomics of colon cancer.

  2011cites this paper
• An association between DNA repair gene polymorphisms and survival in patients with resected non-small cell lung cancer

  2011cites this paper
• APEX microarray panel for genotyping polymorphisms in cancer chemotherapy and estimation frequencies in a Slovak population.

  2011cites this paper
• Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer.

  2011cites this paper
• Treatment recommendations for metastatic colorectal cancer

  2011cites this paper
• Predictive Factors of Complete Response to Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer

  2010cites this paper
• Biomarker-based prediction of response to therapy for colorectal cancer: current perspective.

  2010cites this paper
• MGMT −535G>T polymorphism is associated with prognosis for patients with metastatic colorectal cancer treated with oxaliplatin-based chemotherapy

  2010cites this paper
• Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform.

  2010cites this paper
• Pharmacogenetics in Colorectal Cancer

  2010cites this paper
• The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens

  2010cites this paper
• Nanotechnology in cancer therapy: targeting the inhibition of key DNA repair pathways.

  2010cites this paper
• Incorporating Pharmacogenomics into Cancer Therapy

  2010cites this paper
• [Recent developments of pharmacogenomics in the treatment of colorectal cancers].

  2010cites this paper
• Caractérisation pharmacogénétique des facteurs de résistance et de toxicité de l'Oxaliplatine et de l'Irinotécan dans les tumeurs colorectales

  2010cites this paper
• Pharmacogenetics in oncology: a promising field.

  2010cites this paper
• XPD DNA nucleotide excision repair gene polymorphisms associated with DNA repair deficiency predict better treatment outcomes in secondary acute myeloid leukemia.

  2010cites this paper
• Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response.

  2010cites this paper
• 6 – Farmacogenética del tratamiento quimioterápico del cáncer colorrectal*

  2010cites this paper
• Pharmacogenetic analyses of hematotoxicity in advanced gastric cancer patients receiving biweekly fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

  2009cites this paper
• AJG Series: Molecular Biology for Clinicians

  2009cites this paper
• Biomarkers and drug development 2009.

  2009cites this paper
• Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial.

  2009cites this paper
• DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.

  2009cites this paper
• Pharmacogenetics and biomarkers in colorectal cancer

  2009cites this paper
• Haplotypes of XRCC1 and survival outcome in patients with metastatic breast cancer

  2009cites this paper
• Basic Principles and Technologies for Deciphering the Genetic Map of Cancer

  2009cites this paper
• Platinum pathway.

  2009cites this paper
• Personalized Medicine in the Clinical Management of Colorectal Cancer

  2009cites this paper
• Molecular Markers for Individualized Therapy in Colorectal Cancer: Progress Towards a Pharmacogenomics Array

  2009cites this paper
• The association of XRCC1 gene single nucleotide polymorphisms with response to neoadjuvant chemotherapy in locally advanced cervical carcinoma

  2009cites this paper
• Pharmacogenomics of Taxane/Platinum Therapy in Ovarian Cancer

  2009cites this paper
• Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie.

  2009cites this paper
• Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy

  2009cites this paper